Finlands Akademi
Finansieringsbeslut
 
Sökande / Kontakt person Mirtti, Tuomas
Organisation Helsingfors universitet
Projektets titel Digital Molecular Pathology of the Prostate
Beslutnr 323098
Beslutsdatum 06.05.2019
Finansierings period 01.09.2019 - 31.08.2023
Finansiering 282 537
WebFOCUS Report
Beskrivning av projektet
Most of the prostate cancers detected to date are cured, but up to 15% of men diagnosed with PCa will die due to disease. By biopsy-based guidelines, clinicians stratify patients into risk groups and recommend active surveillance or radical treatment, as no other clinically validated predictive markers exist. The physicians experience uncertainty at the treatment selection, possibly causing exposure to harmful side effects of treatment to those men who would not harbor any significant (metastasizing or lethal) PCa. There is need for improvement in diagnostic imaging, which should be based on the knowledge about the tissue biology and prognostic characteristics of detectable changes. This project aims to determine biological changes that depict treatment resistant and lethal PCa from indolent PCa. We also correlate the relevant biological markers in the MRI-detected PCa. With collaborators, including companies, the goal is to find new solutions for more individual treatment selection.